Competition for Eli Lilly’s Alimta (pemetrexed) blockbuster continues to elude the US market after the US Court of Appeals for the Federal Circuit ruled that a lower court was correct to grant the originator’s motion for summary judgment of infringement against 505(b)(2) new drug application sponsor Apotex under the doctrine of equivalents.
The panel of three appeals court judges found that District Court for the Southern District of Indiana Judge Tanya Walton...






